Pharma leaders urge UK Government not to cut spending
September 9, 2015Research and Development Autumn spending review, George Osborne, R&D, government, research, research and development, research funding
Representatives of more than 200 life sciences organisations have urged the UK government to protect the sector from spending cuts. …
Neurimmune kicks off late-stage Alzheimer’s study
September 9, 2015Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology
Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab. The …
GSK suffers Breo late-stage trial blow
September 9, 2015Research and Development COPD, GSK, Revlar, asthma, breo, clinical trial, phase III
GSK has hit a setback in its plans to expand sales of its blockbuster asthma treatment Breo, after a major …
Mission Therapeutics appoints new chief medical officer
September 9, 2015Medical Communications, Research and Development Dr Michael Koslowski, Mission Therapeutics
Mission Therapeutics has announced the appointment of Dr Michael Koslowski as chief medical officer. Dr Koslowski brings over 15 years’ …
Yabao Pharmaceutical and UniSA embark on joint venture
September 9, 2015Research and Development Cancer, Yabao Pharmaceutical
Yabao Pharmaceutical and the University of South Australia (UniSA) have joined together in a collaboration to develop new treatments for …
Biocair International Ltd achieves AEO approval
September 8, 2015Medical Communications Biocair
We are pleased to announce that as of 8th September 2015 Biocair International Ltd is an Authorised Economic Operator (AEO). …
Sun Pharma strengthens opiates business
September 8, 2015Manufacturing and Production Australia, GSK, Sun Pharma, manufacturing and production, opiates
Sun Pharmaceutical Industries has strengthened its global opiates manufacturing business with the acquisition of two Australian manufacturing facilities from GlaxoSmithKline. …
New treatment option for ovarian cancer patients in Scotland
September 8, 2015Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer
The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …
EMA launches project to boost early patient access to drugs
September 8, 2015Research and Development EMA, European Medicines Agency, MAPPs, adaptive pathways, drug development, market access
The EMA is launching an adaptive pathway project to bring new medicinal products to market in Europe. The ADAPT SMART …
Novo Nordisk expands in Denmark
September 8, 2015Manufacturing and Production, Research and Development Denmark, Novo Nordisk, haemophilia API
Novo Nordisk has announced that the company is investing 500 million Danish kroner (about £48.8 million) in a new 19,000 …
Novo joins forces with MIT innovating drug devices
September 8, 2015Manufacturing and Production, Research and Development Novo Nordisk
Novo Nordisk has initiated a research collaboration with the Langer Laboratory at the Massachusetts Institute of Technology for what is …
Wave appoints Mehwish Abdeali as senior programme executive
September 8, 2015Medical Communications Mehwish Abdeali, wave
Mehwish Abdeali has been appointed as senior programme executive at Wave, a specialist medical education company. Mehwish joins Wave from …
ABPI ‘deeply concerned’ by slow UK drugs uptake
September 7, 2015Sales and Marketing ABPI, PPRS, Pharmaceutical Price Regulation Scheme, drugs bill, market access, medicines bill
The UK pharma industry paid £209 million to underwrite the UK medicines bill in second quarter of 2015, according to …
NICE recommends Keytruda for advanced skin cancer
September 7, 2015Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer
NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS. …
Pharma industry to deliver strong growth – despite price pressure
September 7, 2015Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry
The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …
Neurology comes to the fore
September 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology
Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
Celgene threatens to scale back UK clinical trial investment after CDF snub
September 4, 2015Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs
One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
Pfizer completes $15 billion Hospira acquisition
September 4, 2015Biosimilar Drugs, Hospira, Pfizer, mergers and acquisitions
Pfizer has completed its acquisition of Illinois-based injectable drugs and infusion device specialist Hospira for around $15 billion.The deal, first announced …
Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Companies braced for new round of cancer cuts
September 4, 2015Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts
Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
